drugset / Trial / NCT01342913
A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the 24-hour spirometry effect (FEV1) of Fluticasone Furoate/Vilanterol 100/25mcg once daily compared with Salmeterol/Fluticasone Propionate 50/500mcg twice daily over a 12-week treatmen period in subjects with COPD.
Timeline
- Start
- 2011-02-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluticaosne Propionate 500mcg/Salmeterol 50mcg | Unknown | 500 ug | Inhaled |
| Subject | Fluticasone Furoate | Other / unclassified | 100 ug | Inhaled |
| Comparator | Salmeterol | Other / unclassified | 50 ug | Inhaled |
| Subject | Vilanterol | Other / unclassified | 25 ug | Inhaled |